Telix publishes Phase 1 prostate cancer therapy study in Cancers journal
Go back to Telix publishes Phase 1 prostate cancer therapy study in Cancers journal| TRANS-LUX CORPORATION (NASDAQ: TLX) | Delayed: 10.51 +0.19 (1.84%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.32 | 52 Week High | $2.18 | |||
| Open | $10.47 | 52 Week Low | $0.30 | |||
| Day High | $10.54 | P/E | N/A | |||
| Day Low | $10.40 | EPS | $-3.32 | |||
| Volume | 121,276 | |||||
